Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
View Full Paper
Ask AI
Bookmark
Share
Key Points
To assess 5-year survival rates and clinical characteristics of patients benefiting from dabrafenib and trametinib in metastatic melanoma.
Analyzed pooled data from COMBI-d and COMBI-v trials involving 563 previously untreated patients.
Patients received dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) with a median follow-up of 22 months.
Focused on primary endpoints of progression-free survival and overall survival rates.
Progression-free survival rates were 19% at 5 years (95% CI, 15 to 22).
Overall survival rates were 34% at 5 years (95% CI, 30 to 38).
109 patients (19%) had a complete response, with a 5-year overall survival rate of 71% (95% CI, 62 to 79).
Discussion
No takes yet. Share an insight, caveat, or question.
Implication
Randomized trial evaluates 5-year survival rates of dabrafenib plus trametinib in metastatic melanoma, suggesting durability of benefit from treatment.